文献速递新发突发、热带与寄生虫病

低风疹疫苗应答与接种BNT162b2后抗SARS-CoV-2免疫应答降低相关:一项横断面研究

Association between a low response to rubella vaccination and reduced anti-severe acute respiratory syndrome coronavirus 2 immune response after vaccination with BNT162b2: a cross-sectional study.
PubMed 文献 · Clin Microbiol Infect · 2022-09-20

本研究利用接种两剂BNT162b2疫苗的医护人员数据,开展单中心横断面研究,探讨对麻疹、风疹和乙肝疫苗低应答者接种SARS-CoV-2疫苗后能否获得足够抗体。2021年5月至6月,在第二剂接种至少2周后检测抗SARS-CoV-2刺突IgG抗体。多变量线性回归显示,风疹疫苗低应答者接种两剂BNT162b2后抗S IgG滴度获得显著较低。

要点

  • 714名参与者接种两剂BNT162b2后抗S IgG均阳性(≥50.0 AU/mL),中位数7126.8 AU/mL。
  • 风疹疫苗低应答者接种BNT162b2后抗S IgG滴度获得显著较低(标准化系数β -0.110)。
  • 风疹疫苗低应答可能是SARS-CoV-2疫苗应答降低的潜在预测因素。

核心结论

  • 低风疹疫苗应答是SARS-CoV-2疫苗应答降低的潜在预测因素。
  • 需进一步研究以确定低风疹疫苗应答是否与SARS-CoV-2疫苗诱导免疫应答的持久性相关。

研究设计与样本

  • 单中心横断面研究,利用接种两剂BNT162b2疫苗(BioNTech/Pfizer)的医护人员数据。
  • 2021年5月至2021年6月,在第二剂BNT162b2接种至少2周后检测抗SARS-CoV-2刺突(anti-S)IgG抗体。
  • 共714名参与者。

主要发现

  • 全部714名参与者接种两剂BNT162b2后抗S IgG滴度阳性(≥50.0 AU/mL),中位数7126.8 AU/mL,四分位距4496.2-11296.8。
  • 对麻疹、风疹和HBV疫苗接种低应答者分别为323名(45.2%)、131名(18.3%)和43名(6.0%)。
  • 多变量线性回归分析中,风疹疫苗低应答者接种两剂BNT162b2后抗S IgG滴度获得显著较低(标准化系数β -0.110;95%CI -0.175至-0.044)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需进一步研究以确定低风疹疫苗应答是否与SARS-CoV-2疫苗诱导免疫应答的持久性相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Some vaccinated individuals fail to acquire an adequate immune response against infection. We aimed to determine whether mRNA severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination could induce a sufficient immune response against SARS-CoV-2 in low responders to other vaccinations. METHODS: Using data from health-care workers who received two doses of the BNT162b2 vaccine (BioNTech/Pfizer), we conducted a single-centre, cross-sectional study to determine whether low responders to measles, rubella, and hepatitis B virus (HBV) vaccinations could acquire sufficient antibodies after SARS-CoV-2 vaccination. From May 2021 to June 2021, participants were tested for anti-SARS-CoV-2 spike (anti-S) IgG antibodies at least 2 weeks after the second dose of BNT162b2. The association between a low response to measles, rubella, and HBV vaccinations and the post-vaccination anti-S IgG titre was evaluated using the multivariable linear regression analysis. RESULTS: All 714 participants were positive for the anti-S IgG titre (≥50.0 AU/mL) after two doses of BNT162b2 (median, 7126.8 AU/mL; interquartile range, 4496.2-11 296.8). There were 323 (45.2%), 131 (18.3%), and 43 (6.0%) low responders to measles, rubella, and HBV vaccinations, respectively. In the multivariable linear regression analysis, low responders to rubella vaccination had significantly low acquisition of the anti-S IgG titre after two doses of the BNT162b2 vaccine (standardized coefficient β, -0.110; 95% CI, -0.175 to -0.044). CONCLUSIONS: A low response to rubella vaccination is a potential predictor of a reduced response to SARS-CoV-2 vaccination. Further studies are needed to determine whether a low response to rubella vaccination is associated with the durability of SARS-CoV-2 vaccination-induced immune response.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Nakaharai K, Nakazawa Y, Mishima Y, et al. Association between a low response to rubella vaccination and reduced anti-severe acute respiratory syndrome coronavirus 2 immune response after vaccination with BNT162b2: a cross-sectional study. Clin Microbiol Infect. 2022. PMID: 36150670. doi:10.1016/j.cmi.2022.09.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。